Ramosetron Hydrochloride Injection
Function and Efficacy
Pharmacological action 1. 5-HT3 receptor antagonism In the 5-hydroxytryptamine-induced guinea pig isolated colon contraction test and rat and ferret heart rate slowing reflex (Bezold-Jarisch reflex) test, this drug showed antagonism to 5-HT3 receptors. 2. Inhibition of vomiting induced by anti-malignant tumor drugs This drug showed an inhibitory effect on vomiting induced by cisplatin in ferrets when given before vomiting or after the initial vomiting. Anti-malignant tumor drugs such as cisplatin can free 5-hydroxytryptamine from chromaffin cells in the digestive tract. 5-hydroxytryptamine binds to the 5-HT3 receptors present in the gastrointestinal mucosa at the ends of the vagus nerve.
Ingredients
Ramosetron Hydrochloride
| Name | Description | Content | CAS NO. | Manufacturer |
|---|---|---|---|---|
| Ramosetron hydrochlorideIngredients |
1. 5-HT3 receptor antagonism: In the 5-hydroxytryptamine-induced guinea pig isolated colon contraction experiment and the rat and ferret heart rate slowing reflex (Bezold-Jarisch reflex) experiment, it showed an antagonistic effect on the 5-HT3 receptor; 2. Anti-tumor drug-induced vomiting inhibition: This product showed an inhibitory effect on vomiting induced by cisplatin in ferrets when given before vomiting or after the initial vomiting. More |
132907-72-3 | 14 |
Appearance
This product is a colorless clear liquid.
Indication
Prevent and treat gastrointestinal symptoms such as nausea and vomiting caused by anti-malignant tumor drug treatment.
Usage and Dosage
Generally, adults are given 0.3 mg (1 vial) diluted with 5% or 10% glucose solution and saline for intravenous injection once a day. In addition, the dosage can be appropriately increased or decreased according to age and symptoms. If the effect is not obvious, the same dose can be given additionally, but the daily dosage should not exceed 0.6 mg (2 vials).
Adverse Reactions
Adverse reactions occurred in 7 of the 352 cases (2.0%) that underwent safety evaluation before marketing. The main adverse reactions are fever, headache, and heaviness of the head. Severe adverse reactions: People who are allergic to this product may experience allergic-like symptoms such as chest tightness, dyspnea, wheezing, facial flushing, redness, itching, cyanosis, low blood pressure, and even shock. The incidence rate is not yet clear. In addition, there have been reports of epileptic seizures with the use of other 5-HT3 receptor antagonist antiemetics abroad. Other adverse reactions: less than 0.1% to 1% headache, heaviness of the head, diarrhea, body fever, fever in the head, and numbness of the tongue. The incidence rate is unclear redness, rash, itching, constipation, increased BUN, and blood creatinine
Precautions
Patients with a history of allergy to the ingredients of this drug are prohibited from using it;
Drug Interactions
This drug may react with mannitol injection, bumetanide injection, furosemide injection, etc., so do not use them together. However, it can be used by adding 200ml of normal saline to furosemide injection containing 20mg of furanilamide and mixing with one ampoule of this drug.
Storage
Protect from light and store at room temperature. The validity period is tentatively 24 months.
Packaging Specification
2ml:0.3mg
Manufacturer
Avanc Pharmaceutical Co., Ltd.
-
Founded in:
2002-01-28 -
Address:
No. 55, Songshan Street, Taihe District, Jinzhou City, Liaoning Province -
Tax NO.:
91210700734224812X -
Registered Funds:
660 million yuan -
Website:
-
Email: